His research is focused on defining and developing precision therapies targeting the genetic mutations that drive tumorigenesis. Most recently, his efforts have turned towards using single cell sequencing to discover tumor subclonal populations that are responsible for relapse and refractory disease. He is actively engaged in the Children's Oncology group working on pediatric soft tissue sarcomas to investigate the utility of using mutational information as biomarkers for the diagnosis and management of pediatric Rhabdomyosarcoma.